Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2

Molecular Cell

Volumn 22, Issue 6, 2006, Pages 719-729

  Xia, Bing ^a   Sheng, Qing ^a   Nakanishi, Koji ^b   Ohashi, Akihiro ^c   Wu, Jianmin ^c   Christ, Nicole ^b   Liu, Xinggang ^a   Jasin, Maria ^b   Couch, Fergus J ^c   Livingston, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Mayo Clinic   (United States)

Author keywords

CELLCYCLE; DNA

Indexed keywords

BINDING PROTEIN; BRCA2 PROTEIN; PALB2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CELL NUCLEUS MATRIX; CHEMICAL ANALYSIS; CHROMATIN; CONTROLLED STUDY; CYTOCHEMISTRY; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN STABILITY;

BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMATIN; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HELA CELLS; HUMANS; MUTATION, MISSENSE; NUCLEAR MATRIX; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTEIN BINDING; RECOMBINATION, GENETIC; S PHASE; TUMOR SUPPRESSOR PROTEINS;

EID: 33745200945     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2006.05.022     Document Type: Article

References (56)

1. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
2. Chen J., Silver D.P., Walpita D., Cantor S.B., Gazdar A.F., Tomlinson G., Couch F.J., Weber B.L., Ashley T., Livingston D.M., and Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell 2 (1998) 317-328
3. Chen P.L., Chen C.F., Chen Y., Xiao J., Sharp Z.D., and Lee W.H. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc. Natl. Acad. Sci. USA 95 (1998) 5287-5292
4. Couch F.J., Farid L.M., DeShano M.L., Tavtigian S.V., Calzone K., Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat. Genet. 13 (1996) 123-125
5. Daniels M.J., Wang Y., Lee M., and Venkitaraman A.R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306 (2004) 876-879
6. Davies A.A., Masson J.Y., McIlwraith M.J., Stasiak A.Z., Stasiak A., Venkitaraman A.R., and West S.C. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 7 (2001) 273-282
7. Debnath J., Muthuswamy S.K., and Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30 (2003) 256-268
8. Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., and West S.C. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434 (2005) 598-604
9. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
10. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 (1998) 676-689
11. Fuks F., Milner J., and Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17 (1998) 2531-2534
12. Groisman R., Polanowska J., Kuraoka I., Sawada J., Saijo M., Drapkin R., Kisselev A.F., Tanaka K., and Nakatani Y. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113 (2003) 357-367
13. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 (2002) 606-609
14. Huber L.J., and Chodosh L.A. Dynamics of DNA repair suggested by the subcellular localization of Brca1 and Brca2 proteins. J. Cell. Biochem. 96 (2005) 47-55
15. Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin S.F., Milner J., Brown L.A., Hsu F., Gilks B., et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115 (2003) 523-535
16. Hussain S., Witt E., Huber P.A., Medhurst A.L., Ashworth A., and Mathew C.G. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum. Mol. Genet. 12 (2003) 2503-2510
17. Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S., Davies A., Masson J.Y., Moses R., West S.C., et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum. Mol. Genet. 13 (2004) 1241-1248
18. Kraakman-van der Zwet M., Overkamp W.J., van Lange R.E., Essers J., van Duijn-Goedhart A., Wiggers I., Swaminathan S., van Buul P.P., Errami A., Tan R.T., et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22 (2002) 669-679
19. Lee M., Daniels M.J., and Venkitaraman A.R. Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 23 (2004) 865-872
20. Lomonosov M., Anand S., Sangrithi M., Davies R., and Venkitaraman A.R. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 17 (2003) 3017-3022
21. Lowenfels A.B., and Maisonneuve P. Risk factors for pancreatic cancer. J. Cell. Biochem. 95 (2005) 649-656
22. Lu H., Guo X., Meng X., Liu J., Allen C., Wray J., Nickoloff J.A., and Shen Z. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol. Cell. Biol. 25 (2005) 1949-1957
23. Marmorstein L.Y., Kinev A.V., Chan G.K., Bochar D.A., Beniya H., Epstein J.A., Yen T.J., and Shiekhattar R. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 104 (2001) 247-257
24. Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J., and Ashworth A. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol. Cell. Biol. 19 (1999) 4633-4642
25. Milner J., Ponder B., Hughes-Davies L., Seltmann M., and Kouzarides T. Transcriptional activation functions in BRCA2. Nature 386 (1997) 772-773
26. Moynahan M.E., Pierce A.J., and Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7 (2001) 263-272
27. Nakanishi K., Yang Y.G., Pierce A.J., Taniguchi T., Digweed M., D'Andrea A.D., Wang Z.Q., and Jasin M. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. USA 102 (2005) 1110-1115
28. Nakatani Y., and Ogryzko V. Immunoaffinity purification of mammalian protein complexes. Methods Enzymol. 370 (2003) 430-444
29. Narod S.A. Modifiers of risk of hereditary breast and ovarian cancer. Nat. Rev. Cancer 2 (2002) 113-123
30. Nordling M., Karlsson P., Wahlstrom J., Engwall Y., Wallgren A., and Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res. 58 (1998) 1372-1375
31. Patel K.J., Yu V.P., Lee H., Corcoran A., Thistlethwaite F.C., Evans M.J., Colledge W.H., Friedman L.S., Ponder B.A., and Venkitaraman A.R. Involvement of Brca2 in DNA repair. Mol. Cell 1 (1998) 347-357
32. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., and Venkitaraman A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420 (2002) 287-293
33. Schoenfeld A.R., Apgar S., Dolios G., Wang R., and Aaronson S.A. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol. Cell. Biol. 24 (2004) 7444-7455
34. Scully R., Chen J., Ochs R.L., Keegan K., Hoekstra M., Feunteun J., and Livingston D.M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90 (1997) 425-435
35. Sharan S.K., Morimatsu M., Albrecht U., Lim D.S., Regel E., Dinh C., Sands A., Eichele G., Hasty P., and Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386 (1997) 804-810
36. Shin S., and Verma I.M. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription. Proc. Natl. Acad. Sci. USA 100 (2003) 7201-7206
37. Simard J., Dumont M., Labuda D., Sinnett D., Meloche C., El-Alfy M., Berger L., Lees E., Labrie F., and Tavtigian S.V. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr. Relat. Cancer 10 (2003) 225-259
38. Sowter H., and Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 26 (2005) 1651-1656
39. Spain B.H., Larson C.J., Shihabuddin L.S., Gage F.H., and Verma I.M. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc. Natl. Acad. Sci. USA 96 (1999) 13920-13925
40. Taniguchi T., and D'Andrea A.D. The molecular pathogenesis of fanconi anemia: recent progress. Blood 107 (2006) 4223-4233
41. Tarsounas M., Davies D., and West S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 22 (2003) 1115-1123
42. Turner N., Tutt A., and Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr. Opin. Pharmacol. 5 (2005) 388-393
43. Tutt A., Gabriel A., Bertwistle D., Connor F., Paterson H., Peacock J., Ross G., and Ashworth A. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9 (1999) 1107-1110
44. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 (2002) 171-182
45. Wang X., Andreassen P.R., and D'Andrea A.D. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol. Cell. Biol. 24 (2004) 5850-5862
46. Welcsh P.L., and King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10 (2001) 705-713
47. West S.C. Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell Biol. 4 (2003) 435-445
48. Wong A.K., Pero R., Ormonde P.A., Tavtigian S.V., and Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem. 272 (1997) 31941-31944
49. Wooster R., and Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 348 (2003) 2339-2347
50. Wu K., Hinson S.R., Ohashi A., Farrugia D., Wendt P., Tavtigian S.V., Deffenbaugh A., Goldgar D., and Couch F.J. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65 (2005) 417-426
51. Xia F., Taghian D.G., DeFrank J.S., Zeng Z.C., Willers H., Iliakis G., and Powell S.N. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc. Natl. Acad. Sci. USA 98 (2001) 8644-8649
52. Yang H., Jeffrey P.D., Miller J., Kinnucan E., Sun Y., Thoma N.H., Zheng N., Chen P.L., Lee W.H., and Pavletich N.P. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297 (2002) 1837-1848
53. Yang H., Li Q., Fan J., Holloman W.K., and Pavletich N.P. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature 433 (2005) 653-657
54. Yu D.S., Sonoda E., Takeda S., Huang C.L., Pellegrini L., Blundell T.L., and Venkitaraman A.R. Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol. Cell 12 (2003) 1029-1041
55. Yu V.P., Koehler M., Steinlein C., Schmid M., Hanakahi L.A., van Gool A.J., West S.C., and Venkitaraman A.R. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 14 (2000) 1400-1406
56. Yuan S.S., Lee S.Y., Chen G., Song M., Tomlinson G.E., and Lee E.Y. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59 (1999) 3547-3551